Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) FCF Margin (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed FCF Margin for 7 consecutive years, with 36.62% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 327381.0% to 36.62% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 89.03% through Dec 2025, up 14576.0% year-over-year, with the annual reading at 89.03% for FY2025, 14576.0% up from the prior year.
  • FCF Margin hit 36.62% in Q4 2025 for BridgeBio Pharma, up from 91.66% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 3445.71% in Q2 2024 to a low of 39042.01% in Q3 2022.
  • Historically, FCF Margin has averaged 6369.03% across 5 years, with a median of 3430.9% in 2023.
  • Biggest YoY gain for FCF Margin was 7942400bps in 2021; the steepest drop was -3526199bps in 2021.
  • Year by year, FCF Margin stood at 1237.48% in 2021, then tumbled by -324bps to 5240.86% in 2022, then tumbled by -38bps to 7216.79% in 2023, then soared by 54bps to 3310.42% in 2024, then skyrocketed by 99bps to 36.62% in 2025.
  • Business Quant data shows FCF Margin for BBIO at 36.62% in Q4 2025, 91.66% in Q3 2025, and 72.97% in Q2 2025.